immunoglobulin heavy diversity 3-16Genealiases: []
Q-omics provides the consensus-scored IGHD3-16 profile across patient tissues and cancer cell-line models. IGHD3-16 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, IGHD3-16 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, IGHD3-16 RNA expression shows 9,549 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, LUAD, and LSCC as cancer lineages where IGHD3-16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHD3-16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHD3-16 survival associations across molecular data types. IGHD3-16 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHD3-16 RNA expression–survival associations across cancer types. High IGHD3-16 expression shows unfavorable associations in STAD and LAML, but favorable associations in UCEC, LUAD, PAAD and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for IGHD3-16 RNA expression.
This table summarizes IGHD3-16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGHD3-16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHD3-16 shows lower tumor expression in COAD and STAD and higher tumor expression in LUAD and KIRC. The LUAD box plot shows higher IGHD3-16 RNA expression in tumor versus normal tissue (log2 FC = +1.145, t-test p < 0.001).
This table shows molecular features associated with IGHD3-16 in patient tissues and cancer cell lines. In patient samples, IGHD3-16 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
